Home
New Filings
2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
March 2021
February 2021
January 2021
2020
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
2019
December 2019
February 2019
January 2019
Archive
2018
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
February 2018
January 2018
2017
December 2017
November 2017
October 2017
September 2017
August 2017
July 2017
June 2017
May 2017
April 2017
March 2017
February 2017
January 2017
2016
December 2016
November 2016
October 2016
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
January 2016
2015
December 2015
November 2015
October 2015
September 2015
August 2015
July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
2014
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
2013
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
2012
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
2011
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
2010
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
2009
December 2009
November 2009
October 2009
Flagship Global Corp - FORM S-1/A - EX-99.3 - PROVISIONAL PATENT - NON INVASIVE GLUCOSE TESTER (FILED MARCH 20, 2015) - April 29, 2015
Attached files
file
filename
S-1/A - S-1/A - Flagship Global Corp
amendment_s1a7.htm
EX-3.1 - ARTICLES OF INC. - Flagship Global Corp
articlesofinc.htm
EX-23.1 - AUDITOR CONSENT - Flagship Global Corp
consent.htm
EX-5.1 - LEGAL OPINION LETTER PERTAINING TO SECURITIES - Flagship Global Corp
legalopinion.htm
EX-99.4 - PROVISIONAL PATENT - THERMAL DETECTION OF INTRAVENOUS INFILTRATION (FILED MARCH 20, 2015) - Flagship Global Corp
exhibit994.htm
EX-3.2 - BY-LAWS - Flagship Global Corp
bylaws.htm
EX-99.1 - PROVISIONAL PATENT - NON INVASIVE GLUCOSE TESTER (FILED MAY 20, 2014) - Flagship Global Corp
exhibit991.htm
EX-99.2 - PROVISIONAL PATENT - THERMAL DETECTION OF INTRAVENOUS INFILTRATION (FILED MAY 20, 2014) - Flagship Global Corp
exhibit992.htm
EX-5.2 - ATTORNEY OPINION LETTER PERTAINING TO RIGHTS TO PROVISIONAL PATENTS - Flagship Global Corp
opinion_patents.htm
EX-10.2 - ASSIGNMENT AGREEMENT(S) DATED MARCH 6, 2015 AND MARCH 9, 2015 (INVASIVE BLOOD GLUCOSE TESTER) - Flagship Global Corp
assignment_nibgt.htm
EX-10.1 - ASSIGNMENT AGREEMENT DATED JULY 22, 2009 - Flagship Global Corp
assignment_agreement.htm
EX-23.2 - CONSENT OF BEFUMO & SCHAEFFER PLLC - Flagship Global Corp
exhibit232.htm
EX-10.3 - ASSIGNMENT AGREEMENT(S) DATED MARCH 6, 2015 AND MARCH 9, 2015 (THERMAL DETECTION OF INTRAVENOUS INFILTRATION) - Flagship Global Corp
assignment_tdoi.htm
EX-99.3
14
exhibit993.htm
PROVISIONAL PATENT - NON INVASIVE GLUCOSE TESTER (FILED MARCH 20, 2015)
Flagship Global Corp Reports
03/14/2016 - 10-K
04/14/2017 - 10-K
04/17/2018 - 10-K
06/15/2015 - 10-Q
08/13/2015 - 10-Q
11/13/2015 - 10-Q
05/03/2016 - 10-Q
08/11/2016 - 10-Q
11/16/2016 - 10-Q
05/18/2017 - 10-Q
11/14/2017 - 10-Q
05/21/2018 - 10-Q
Also read
Park national corp /oh/ - 8-k, other events financial statements and exhibits
Primoris services corp - 8-k, entry into a material definitive agreement financial statements and exhibits
American renal associates holdings, inc. - 8-k, regulation fd disclosure other events financial statements and exhibits
Spero therapeutics, inc. - 8-k, results of operations and financial condition other events financial statements and exhibits
Cactus, inc. - 8-k, results of operations and financial condition regulation fd disclosure financial statements and exhibits